NRT6003
/ Chengdu New Radiomedicine Technology
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
April 25, 2025
Safety and Efficacy of TareSphere Injection and cTACE in Patients With Unresectable HCC
(clinicaltrials.gov)
- P3 | N=108 | Recruiting | Sponsor: Chengdu New Radiomedicine Technology Co. LTD. | Not yet recruiting ➔ Recruiting
Enrollment open • Hepatocellular Cancer • Oncology • Solid Tumor
April 03, 2025
A Multicentre, Prospective, Open-label Randomised Controlled Clinical Study Comparing the Efficacy and Safety of NRT6003 Injection and Traditional Meridian Embolism in Patients with Non-operable Hepatocellular Cancer in China
(clinicaltrials.gov)
- P3 | N=6 | Not yet recruiting | Sponsor: Zhongda Hospital
New P3 trial • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor
March 28, 2025
Safety and Efficacy of TareSphere Injection and CTACE in Patients with Unresectable HCC
(clinicaltrials.gov)
- P3 | N=108 | Not yet recruiting | Sponsor: Chengdu New Radiomedicine Technology Co. LTD.
New P3 trial • Hepatocellular Cancer • Oncology • Solid Tumor
March 24, 2025
Safety and Efficacy of TareSphere in Patients with Unresectable Hepatocellular Carcinoma
(clinicaltrials.gov)
- P1 | N=40 | Active, not recruiting | Sponsor: Chengdu New Radiomedicine Technology Co. LTD. | Recruiting ➔ Active, not recruiting
Enrollment closed • Hepatocellular Cancer • Oncology • Solid Tumor
March 15, 2024
Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Chengdu New Radiomedicine Technology Co. LTD.
New P1 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor
1 to 5
Of
5
Go to page
1